Department of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Department of Endocrinology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
J Am Heart Assoc. 2019 Aug 20;8(16):e012428. doi: 10.1161/JAHA.119.012428. Epub 2019 Aug 14.
Background Several lipid-lowering therapies reduce CRP (C-reactive protein) independently of LDL-C (low-density lipoprotein cholesterol) reduction, but the association between CRP parameters and benefits from more-intensive LDL-C lowering is inconclusive. We aimed to determine whether the benefits of more- versus less-intensive LDL-C lowering on cardiovascular events related to baseline, achieved, or magnitude of reduction in CRP concentrations. Methods and Results PubMed, EMBASE, and Cochrane were searched through July 2, 2018. We included randomized controlled cardiovascular outcome trials of LDL-C lowering with statins or ezetimibe. Two reviewers independently extracted study data and rated study quality. Data were analyzed using meta-analysis and metaregression analysis. Rate ratios of mortality and cardiovascular outcomes associated with baseline, achieved, and magnitude reduction of CRP concentration were calculated. Twenty-four trials were included, with 171 250 patients randomly assigned to more- or less-intensive LDL-C-lowering treatments. Median follow-up duration was 4.2 years. More-intensive LDL-C lowering resulted in a significant reduction in incidences of all outcomes. Compared with less-intensive LDL-C lowering, more-intensive LDL-C lowering was associated with less reductions in myocardial infarction with a higher baseline CRP concentration (change in rate ratios per 1-mg/L increase in log-transformed CRP, 1.12 [95% CI, 1.04-1.22; P=0.007]), but not other outcomes. Similar risk reductions occurred for more- versus less-intensive LDL-C-lowering therapy regardless of the magnitude of CRP reduction or the achieved CRP level for all outcomes. Conclusions Baseline CRP concentrations might be associated with the benefits of LDL-C lowering on myocardial infarction, but no other outcomes, whereas the achieved and magnitude of reduction in CRP did not seem to have an important association.
几种降脂疗法可独立于 LDL-C(低密度脂蛋白胆固醇)降低而降低 CRP(C 反应蛋白),但 CRP 水平与更强化 LDL-C 降低获益之间的关系尚无定论。本研究旨在确定与基线 CRP 浓度、达到的 CRP 浓度或 CRP 浓度降低幅度相关的心血管事件,更强化与更不强化 LDL-C 降低治疗的获益是否存在差异。
通过 PubMed、EMBASE 和 Cochrane 检索,检索截至 2018 年 7 月 2 日。我们纳入了 LDL-C 降低的他汀类药物或依折麦布的随机对照心血管结局试验。两名评审员独立提取研究数据并评价研究质量。使用荟萃分析和荟萃回归分析进行数据分析。计算死亡率和心血管结局与 CRP 浓度基线、达到的 CRP 浓度和 CRP 浓度降低幅度相关的风险比。共纳入 24 项试验,171250 例患者随机分为更强化与更不强化 LDL-C 降低治疗组。中位随访时间为 4.2 年。与更不强化 LDL-C 降低治疗相比,更强化 LDL-C 降低治疗可显著降低所有结局的发生率。与更不强化 LDL-C 降低治疗相比,基线 CRP 浓度较高的患者,更强化 LDL-C 降低治疗与心肌梗死发生率降低相关(每增加 1mg/L CRP 的对数转换,风险比降低 1.12[95%CI,1.04-1.22;P=0.007]),但与其他结局无关。对于所有结局,与更不强化 LDL-C 降低治疗相比,更强化 LDL-C 降低治疗均显示出相似的风险降低。
基线 CRP 浓度可能与 LDL-C 降低治疗对心肌梗死的获益相关,但与其他结局无关,而 CRP 水平的达到和降低幅度似乎没有重要关联。